Author

J.-P. Delord

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

B. Thibault· 2 shared A. Carrier· 1 shared A. Coste· 1 shared A. Le Naour· 1 shared A. Martinez· 1 shared A. V. Villard· 1 shared B. Bournet· 1 shared B. Couderc· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Thibault

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pancreatic Cancer Intrinsic PI3Kα Activity accelerates Metastasis and rewires Macrophage Component

B. Thibault, F. Ramos-Delgado, E. Pons-Tostivint, N. Therville, C. Cintas, S. Arcucci, S. Cassant-Sourdy, G. Reyes-Castellanos, M. Tosolini, A. V. Villard, C. Cayron, R. Baer, J. Bertrand-Michel, D. Payen, H. Yan, , J. Guillermet-Guibert

This paper identifies PI3K pathway activation as a driver of metastatic progression in pancreatic cancer and shows that targeting PI3K can delay macro-metastatic evolution.

bioRxiv · Sep 23, 2020Cancer Biology

Mesenchymal stromal cells release CXCL1/2/8 and induce chemoresistance and macrophage polarization

B. Couderc, A. Le Naour, M. Prat, R. Mevel, B. Thibault, L. Lemaitre, H. Leray, M. Golzio, L. Lefevre, E. Mery, A. Martinez, G. Ferron, J.-P. Delord, A. Coste

This study identifies CXCL1/2/8 as factors released by cancer-associated mesenchymal stromal cells that induce chemoresistance and macrophage polarization, suggesting CXCR1/2 inhibition as a potential therapeutic strategy.

bioRxiv · Dec 4, 2018 · PreprintCancer Biology